Stopping the medication should be a collaborative decision with your provider, not a unilateral one based on early side effects that might resolve
It underscores the importance of clinical vigilance, appropriate dose titration, and prompt recognition of gastrointestinal intolerance in patients treated with GLP-1 receptor agonists [8]
On Sunday, Lilly released new data about retatrutide, an injectable drug that combines GLP-1 and glucagon, plus another hormone called GIP
Discontinue use and consult a healthcare provider if severe reactions occur
3A), but a significant interaction between time and group was not observed
[DOI] [PMC free article] [PubMed] [Google Scholar] 21.Cadenas E., Davies K.J.A